Stevanato Group Past Earnings Performance
Past criteria checks 2/6
Stevanato Group has been growing earnings at an average annual rate of 19.4%, while the Life Sciences industry saw earnings growing at 16.8% annually. Revenues have been growing at an average rate of 15.3% per year. Stevanato Group's return on equity is 12.9%, and it has net margins of 13.4%.
Key information
19.4%
Earnings growth rate
16.6%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 15.3% |
| Return on equity | 12.9% |
| Net Margin | 13.4% |
| Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Stevanato Group's (NYSE:STVN) Solid Earnings May Rest On Weak Foundations
Mar 15
Stevanato: Destocking And Valuation Risk (Rating Downgrade)
Mar 12Is Stevanato Group S.p.A. (NYSE:STVN) Expensive For A Reason? A Look At Its Intrinsic Value
Feb 09Stevanato: Guidance Reiterated And Supportive Revenue Growth
Nov 22Is Stevanato Group S.p.A. (NYSE:STVN) Worth US$31.6 Based On Its Intrinsic Value?
Oct 22Stevanato: Secular Tailwinds In Biologics Support Downstream Demand
Sep 15Stevanato Group: Undeniable Quality, But Lacking Upside
Jun 14Stevanato Group S.p.A. Just Beat EPS By 5.1%: Here's What Analysts Think Will Happen Next
Mar 05Stevanato Group and Transcoject to provide pre-fillable syringe polymer options for pharma
Jan 24There's Reason For Concern Over Stevanato Group S.p.A.'s (NYSE:STVN) Price
Dec 28Stevanato Group Non-GAAP EPS of $0.14 beats by $0.01, revenue of $245.3M in-line
Nov 08An Intrinsic Calculation For Stevanato Group S.p.A. (NYSE:STVN) Suggests It's 49% Undervalued
Aug 01A Look At The Intrinsic Value Of Stevanato Group S.p.A. (NYSE:STVN)
Apr 19Revenue & Expenses BreakdownBeta
How Stevanato Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,085 | 146 | 114 | 36 |
| 30 Sep 23 | 1,057 | 149 | 116 | 36 |
| 30 Jun 23 | 1,031 | 147 | 117 | 35 |
| 31 Mar 23 | 1,010 | 143 | 117 | 35 |
| 31 Dec 22 | 984 | 143 | 112 | 34 |
| 30 Sep 22 | 924 | 139 | 100 | 33 |
| 30 Jun 22 | 893 | 122 | 95 | 33 |
| 31 Mar 22 | 863 | 125 | 86 | 31 |
| 31 Dec 21 | 844 | 134 | 83 | 30 |
| 30 Sep 21 | 818 | 123 | 82 | 25 |
| 30 Jun 21 | 761 | 121 | 79 | 22 |
| 31 Mar 21 | 718 | 108 | 79 | 19 |
| 31 Dec 20 | 662 | 79 | 79 | 17 |
| 31 Dec 19 | 537 | 39 | 77 | 8 |
Quality Earnings: STVN has a high level of non-cash earnings.
Growing Profit Margin: STVN's current net profit margins (13.4%) are lower than last year (14.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: STVN's earnings have grown by 19.4% per year over the past 5 years.
Accelerating Growth: STVN's earnings growth over the past year (1.9%) is below its 5-year average (19.4% per year).
Earnings vs Industry: STVN earnings growth over the past year (1.9%) exceeded the Life Sciences industry -4.5%.
Return on Equity
High ROE: STVN's Return on Equity (12.9%) is considered low.